JPMorgan analyst Jessica Fye resumes coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Neutral rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage